Many clinicians use the terms "chronic vesicular hand dermatitis," "dyshidrotic eczema," and "pompholyx" interchangeably. We use the terms used by Warshaw and colleagues. [18] They described ...

People with chronic hand eczema (CHE) have reported the serious impact the condition can have on their daily lives in a UK survey. The poll – commissioned by LEO Pharma and supported by Allergy ...

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE). The launch of pan-JAK inhibitor Anzupgo (delgocitinib ...

A significant proportion of patients with chronic hand eczema reported fear of future health affects due to topical corticosteroid use despite a lack of knowledge on adverse effects, which was ...

The European Commission (EC) has granted marketing authorisation to LEO Pharma’s Anzupgo (delgocitinib) cream for treating ...

Anzupgo is the first topical pan-Janus kinase (JAK) inhibitor to be approved in Switzerland specifically for moderate to ...

Atopic Dermatitis, commonly known as eczema, manifests as chronic, itchy, and inflamed skin persisting ... Dyshidrotic Dermatitis, affecting hands and feet with blisters and itching, occurs in 5-20% ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

The indication is for the treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate ...